674 reports of this reaction
3.6% of all EFAVIRENZ reports
#4 most reported adverse reaction
VIRAL MUTATION IDENTIFIED is the #4 most commonly reported adverse reaction for EFAVIRENZ, manufactured by Aurobindo Pharma Limited. There are 674 FDA adverse event reports linking EFAVIRENZ to VIRAL MUTATION IDENTIFIED. This represents approximately 3.6% of all 18,805 adverse event reports for this drug.
Patients taking EFAVIRENZ who experience viral mutation identified should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VIRAL MUTATION IDENTIFIED is moderately reported among EFAVIRENZ users, representing a notable but not dominant share of adverse events.
In addition to viral mutation identified, the following adverse reactions have been reported for EFAVIRENZ:
The following drugs have also been linked to viral mutation identified in FDA adverse event reports:
VIRAL MUTATION IDENTIFIED has been reported as an adverse event in 674 FDA reports for EFAVIRENZ. This does not prove causation, but indicates an association observed in post-market surveillance data.
VIRAL MUTATION IDENTIFIED accounts for approximately 3.6% of all adverse event reports for EFAVIRENZ, making it a notable side effect.
If you experience viral mutation identified while taking EFAVIRENZ, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.